Malaria drug candidate faces FDA panel
Executive Summary
Novartis' malaria candidate Coartem (artemether/lumefantrine) will be assessed by the Anti-Infective Drugs Advisory Committee Dec. 3 for the treatment of acute, uncomplicated malaria infection due to Plasmodium falciparum or mixed infections including P. falciparum. The NDA is among the first to obtain a priority review voucher from FDA (1"The Pink Sheet," Sept. 22, 2008, p. 26)
You may also be interested in...
Novartis Coartem Malaria NDA May Be First For Priority Review Voucher
Novartis' pending application for approval of the malaria treatment Coartem (artemether/lumefantrine) puts the company in line to be among the first to obtain a priority review voucher from FDA
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.